Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.64 |
| ▸ | ITK | Q08881 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1468543 | 0.93 | ADORA2A (0.64) | ADORA2AITKOPRM1OPRD1OPRK1 | |
| SCHEMBL1468382 | 0.92 | ADORA2A (0.70) | ADORA2AITKOPRM1OPRD1OPRK1 | |
| SCHEMBL12744889 | 0.90 | ADORA2A (0.71) | ADORA2AITKOPRM1OPRD1OPRK1 | |
| SCHEMBL1468305 | 0.87 | ADORA2A (0.75) | ADORA2AITKOPRM1OPRD1OPRK1 | |
| SCHEMBL12744880 | 0.87 | ADORA2A (0.74) | ADORA2AITKOPRM1OPRD1OPRK1 | |
| SCHEMBL8234780 | 0.87 | ADORA2A (0.50) | ADORA2AOPRK1 | |
| SCHEMBL1468374 | 0.86 | ADORA2A (0.73) | ADORA2AITKOPRM1OPRD1OPRK1 | |
| SCHEMBL1467481 | 0.84 | ADORA2A (0.80) | ADORA2AITK | |
| SCHEMBL4589978 | 0.82 | ADORA2A (0.85) | ADORA2A | |
| SCHEMBL8233527 | 0.80 | ADORA2A (0.54) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2007133983-A2 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ITK 3370/4885OPRM1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.